These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 15531282)

  • 21. Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S).
    Huskey J; Lindenfeld J; Cook T; Targher G; Kendrick J; Kjekshus J; Pedersen T; Chonchol M
    Atherosclerosis; 2009 Jul; 205(1):202-6. PubMed ID: 19124121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.
    Peura P; Martikainen J; Soini E; Hallinen T; Niskanen L
    Curr Med Res Opin; 2008 Jun; 24(6):1823-32. PubMed ID: 18485270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
    Tikkanen MJ; Holme I; Cater NB; Szarek M; Faergeman O; Kastelein JJ; Olsson AG; Larsen ML; Lindahl C; Pedersen TR;
    Am J Cardiol; 2009 Mar; 103(5):577-82. PubMed ID: 19231315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada.
    Rivière M; Wang S; Leclerc C; Fitzsimon C; Tretiak R
    CMAJ; 1997 Apr; 156(7):991-7. PubMed ID: 9099167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial.
    Jönsson B; Cook JR; Pedersen TR
    Diabetologia; 1999 Nov; 42(11):1293-301. PubMed ID: 10550412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
    Johannesson M; Jönsson B; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
    N Engl J Med; 1997 Jan; 336(5):332-6. PubMed ID: 9011785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intermediate lipoproteins, atherosclerosis, and Gofman.
    Soloff LA
    Circulation; 1998 Feb; 97(7):708. PubMed ID: 9495311
    [No Abstract]   [Full Text] [Related]  

  • 28. [Atherosclerosis and simvastatin: new questions for the new millennium].
    Tubaro M; Guido V; Sciarra L; Mustilli M; Carbone MA; D'Errico F
    Ann Ital Med Int; 2000; 15(1):108-14. PubMed ID: 10842900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin.
    Mikhailidis DP; Wierzbicki AS
    Curr Med Res Opin; 2000; 16(2):139-46. PubMed ID: 10893658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Terje Pedersen: a pioneer trialist in preventive cardiology.
    Morris K
    Lancet; 2010 Feb; 375(9716):717. PubMed ID: 20189014
    [No Abstract]   [Full Text] [Related]  

  • 31. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
    Foody JM; Brown WV; Zieve F; Adewale AJ; Flaim D; Lowe RS; Jones-Burton C; Tershakovec AM
    Am J Cardiol; 2010 Nov; 106(9):1255-63. PubMed ID: 21029821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. II. Coronary Heart Disease in the Framingham Study.
    Dawber TR; Moore FE; Mann GV
    Int J Epidemiol; 2015 Dec; 44(6):1767-80. PubMed ID: 26705414
    [No Abstract]   [Full Text] [Related]  

  • 33. [The Scandinavian Simvastatin Survival Study (4S)].
    Gram JB
    Ugeskr Laeger; 1995 Apr; 157(14):2020-1. PubMed ID: 7740647
    [No Abstract]   [Full Text] [Related]  

  • 34. Statins and secondary prevention of coronary heart disease.
    Ahmed M; Griffiths P
    Br J Community Nurs; 2004 Apr; 9(4):160-5. PubMed ID: 15150487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coronary heart disease (CHD)--one or several diseases? Changes in the prevalence and features of CHD.
    Azambuja MI; Levins R
    Perspect Biol Med; 2007; 50(2):228-42. PubMed ID: 17468540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipid abnormalities and coronary heart disease.
    Grundy SM
    Clin Symp; 1997; 49(4):1-32. PubMed ID: 9444788
    [No Abstract]   [Full Text] [Related]  

  • 37. Nutrition and food policy in Norway: effects on reduction of coronary heart disease.
    Norum KR; Johansson L; Botten G; Bjørneboe GE; Oshaug A
    Nutr Rev; 1997 Nov; 55(11 Pt 2):S32-9. PubMed ID: 9420460
    [No Abstract]   [Full Text] [Related]  

  • 38. An Investigation of Coronary Heart Disease in Families: The Framingham Offspring Study.
    Am J Epidemiol; 2017 Jun; 185(11):1093-1102. PubMed ID: 30052741
    [No Abstract]   [Full Text] [Related]  

  • 39. Research related to risk factors.
    Stamler J
    Circulation; 1979 Dec; 60(7):1575-87. PubMed ID: 387286
    [No Abstract]   [Full Text] [Related]  

  • 40. Coronary heart disease in seven countries. 1970.
    Keys A
    Nutrition; 1997 Mar; 13(3):250-2; discussion 249, 253. PubMed ID: 9131696
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.